Teriparatide
A parathyroid-hormone analog with high-fracture-risk osteoporosis indications.
FDA-approved product context
A parathyroid-hormone analog with high-fracture-risk osteoporosis indications.
Reviewed October 10, 2026. Product and route distinctions stay attached to the source; this is not a treatment recommendation.
Evidence and source limits
The October 2024 teriparatide injection label describes PTH 1-34 and specified high-fracture-risk osteoporosis populations, including postmenopausal women, men with primary or hypogonadal osteoporosis, and glucocorticoid-associated osteoporosis.
Warnings include osteosarcoma risk in susceptible groups, hypercalcemia, urolithiasis, orthostatic hypotension and digoxin toxicity. This is not a bone-health recommendation for a general population.
Approval applies to the specific labeled product, route and indication, not every preparation of this ingredient or a wellness mixture. Read the original full label and discuss individual circumstances with a medical professional. No dosing or preparation instructions are included.
Original source: Teriparatide ↗
Interpretation is limited to the source linked above. Educational source review, not independent medical review. No dosing, preparation instructions, seller links or treatment endorsement.